CYP2C19 polymorphism influences Helicobacter pylori eradication (Q27005916)

Helicobacter pylori infectious disease

title

CYP2C19 polymorphism influences Helicobacter pylori eradication (English)

0 references

main subject

Helicobacter pylori

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Chao-Hung Kuo

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chien-Yu Lu

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Hsiang-Yao Shih

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Meng-Chieh Wu

5

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Huang-Ming Hu

6

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Wen-Hung Hsu

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Fang-Jung Yu

8

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Deng-Chyang Wu

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Fu-Chen Kuo

10

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

21 November 2014

1 reference

World Journal of Gastroenterology

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

20

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

43

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

16029-16036

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

10 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

H+/K+-ATPase inhibitors: a patent review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Update on the pharmacogenomics of proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Drug-drug interaction profiles of proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

CYP2C19 polymorphism and proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Review article: pharmacology of esomeprazole and comparisons with omeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Review article: the pharmacology of rabeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy

31 May 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 alpha/beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and t

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3748%2FWJG.V20.I43.16029

Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Efficacy of 1-week proton pump inhibitor triple therapy as first-line Helicobacter pylori eradication regime in Asian patients: is it still effective 10 years on?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239489

Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy

28 November 2018

1 reference

12 December 2020

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection

1 reference

12 December 2020

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects

1 reference

12 December 2020

Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan

1 reference

12 December 2020

CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole

1 reference

12 December 2020

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1 reference

12 December 2020

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

1 reference

12 December 2020

In-vitro activity of lansoprazole against Helicobacter pylori

1 reference

12 December 2020

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

12 December 2020

Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial

1 reference

12 December 2020

Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial

1 reference

12 December 2020

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

1 reference

12 December 2020

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

12 December 2020

Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice

1 reference

12 December 2020

Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies

1 reference

12 December 2020

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

1 reference

12 December 2020

Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human

1 reference

12 December 2020

Effectiveness of Helicobacter pylori therapies in a clinical practice setting

1 reference

12 December 2020

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals

1 reference

12 December 2020

Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy

1 reference

12 December 2020

10.3748/WJG.V20.I43.16029

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25473155%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

2 references